In a landmark decision for pediatric infectious disease management, the U.S. Food and Drug Administration (FDA) has officially granted approval for ViiV Healthcare’s Tivicay PD (dolutegravir) for the treatment of HIV-1 in infants weighing as little as 2 kilograms (approximately 4.4 pounds). This pivotal regulatory expansion removes the previous minimum-age threshold, allowing for the use of this potent antiretroviral in newborns from the very first days of life. By addressing a significant therapeutic void in neonatal care, this development marks a critical step forward in the global effort to eliminate pediatric HIV.
The Core Facts: A New Standard of Care
The approval of Tivicay PD—a dispersible tablet formulation of the integrase strand transfer inhibitor (INSTI) dolutegravir—represents the first time a second-generation integrase inhibitor has been cleared for such a low weight and early age demographic. Previously, the formulation was limited to infants at least four weeks old and weighing at least 3 kilograms (6.6 pounds).
The new label authorizes the use of Tivicay PD in combination with other antiretroviral agents for both treatment-naive and treatment-experienced infants who have not previously been exposed to INSTI-class drugs. This shift is expected to streamline clinical protocols, allowing clinicians to initiate highly effective, tolerable, and simplified treatment regimens immediately upon a confirmed HIV diagnosis in neonates.
A Chronology of Clinical Evolution
The journey toward this approval reflects a decade of pharmaceutical refinement and intensive clinical research aimed at bringing adult-standard HIV care to the youngest patients.
- August 2013: The FDA grants its first approval for Tivicay (dolutegravir) for use in adults and adolescents aged 12 or older who weigh at least 40 kilograms (88.2 pounds).
- 2020: Recognizing the need for pediatric-specific formulations, the FDA approves the dispersible Tivicay PD tablet for children at least four weeks of age and weighing at least 3 kilograms.
- 2025 (CROI): Preliminary results from the IMPAACT 2023 study are presented at the Conference on Retroviruses and Opportunistic Infections (CROI). Data highlights the efficacy of a 5-mg dosing schedule in full-term infants weighing between 2.3 and 3.6 kilograms.
- August 2026: The FDA grants Priority Review, ultimately approving the expanded indication, which lowers the weight requirement to 2 kilograms and eliminates the age restriction entirely.
This trajectory underscores the pharmaceutical industry’s growing commitment to "closing the gap," ensuring that pediatric patients are no longer treated as an afterthought in drug development, but as a priority population.
Supporting Clinical Data: The IMPAACT 2023 Study
The clinical foundation for this regulatory success rests on the NIH-funded IMPAACT 2023 study, a multicenter, phase 1 trial that evaluated the safety, pharmacokinetics, and tolerability of dolutegravir in the first four to six weeks of life.
The study enrolled 48 mother-infant pairs across clinical sites in the United States, South Africa, and Thailand—geographies where perinatal HIV transmission, while declining, remains a public health concern. The infants, all weighing at least 2 kilograms, were administered Tivicay PD starting from birth and were followed for 16 weeks.
The data was compelling: researchers found that the drug concentrations in these newborns reached levels comparable to those observed in adults, which are known to be highly effective at suppressing viral loads. Furthermore, the safety profile among these neonates mirrored that of older children and adults, with no unexpected safety signals reported. This consistency across age groups is vital, as it allows for predictable dosing and monitoring in high-pressure clinical environments.
Official Responses and Expert Perspective
The medical community has greeted the FDA’s decision with optimism, framing it as a long-overdue advancement in neonatal medicine.
Dr. Diana F. Clarke, a professor at the Boston University School of Medicine and lead investigator for the IMPAACT 2023 study, emphasized the gravity of the change in a formal statement. "For too long, newborns living with HIV have had too few treatment options designed and studied to meet their unique needs, despite the importance of starting treatment as early as possible," Dr. Clarke noted. She characterized the expanded approval as "an important advance for the care of newborns," highlighting that it provides clinicians with the tools necessary to intervene at the earliest possible stage of the disease.
The FDA’s decision to grant Priority Review indicates a clear alignment with global health goals. By facilitating faster access to pediatric-appropriate formulations, the regulatory body is actively supporting international guidelines that prioritize early detection and immediate antiretroviral therapy (ART) initiation for infants.
Global and Domestic Implications
While the impact of this drug in the U.S. is significant, its potential on a global scale is profound. UNICEF reports that, without treatment, approximately 50% of infants living with HIV will succumb to the disease before their second birthday.
In the United States, the landscape of perinatal HIV has changed drastically. Due to robust prenatal screening and effective prophylactic care, the rate of mother-to-child transmission has plummeted to 1% or less. Consequently, the number of new pediatric HIV cases in the U.S. has remained under 50 annually since 2018. However, for those rare cases where transmission does occur, the availability of a proven, age-appropriate, and easy-to-administer medication is life-saving.
Globally, the implications are even more urgent. In many low- and middle-income countries, the ability to treat infants with a dispersible tablet—which can be easily dissolved in water or breast milk—simplifies the administration of complex HIV regimens. This reduces the burden on caregivers and increases the likelihood of adherence, which is the cornerstone of preventing rapid disease progression in infants.
Commercial Context: GSK and the HIV Portfolio
From a financial perspective, the expansion of the Tivicay label comes at a time when the broader HIV market is undergoing a transition. GSK, the parent company of ViiV Healthcare, reported 2025 sales of £1.323 billion for the standalone Tivicay brand, a slight decline of 2% compared to the previous year.
However, GSK’s wider HIV portfolio remains a powerhouse of growth, totaling £7.687 billion in 2025—an 11% increase. This growth is primarily driven by the success of newer, long-acting, or simplified therapeutic options such as Dovato, Cabenuva, and Apretude. The approval of Tivicay PD for the youngest infants ensures that the dolutegravir platform remains relevant and essential, even as the market shifts toward newer treatment paradigms.
By continuing to innovate within the pediatric space, ViiV Healthcare maintains its reputation as a leader in HIV therapeutics, balancing the decline of older, legacy products with critical expansions in high-need categories.
Conclusion: A Milestone for Equity in Medicine
The FDA’s approval of Tivicay PD for newborns weighing at least 2 kilograms is more than just a regulatory update; it is a victory for health equity. By acknowledging the unique pharmacological needs of the smallest patients, ViiV Healthcare and the FDA have effectively closed a therapeutic gap that has persisted for years.
As clinical practices adapt to incorporate this new guidance, the focus will now shift toward implementation and ensuring that this formulation reaches the infants who need it most, regardless of their location. For the families of infants born with HIV, this development offers something that was once in short supply: time, stability, and the promise of a healthier future. The success of this initiative serves as a blueprint for future pediatric drug development, proving that with rigorous clinical research and collaborative effort, no patient population is too small to receive the highest standard of medical care.
About the Author
